These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37257190)

  • 1. BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
    Jackson RA; Britton RG; Jayne S; Lehmann S; Cowley CM; Trethewey CS; Smith VM; Schmid R; Fegan C; Walter HS; Dyer MJS
    Blood Adv; 2023 Jul; 7(14):3378-3381. PubMed ID: 37257190
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
    Danilov AV; Herbaux C; Walter HS; Hillmen P; Rule SA; Kio EA; Karlin L; Dyer MJS; Mitra SS; Yi PC; Humeniuk R; Huang X; Zhou Z; Bhargava P; Jürgensmeier JM; Fegan CD
    Clin Cancer Res; 2020 Jun; 26(12):2810-2818. PubMed ID: 32156743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
    Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
    Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
    Gángó A; Alpár D; Galik B; Marosvári D; Kiss R; Fésüs V; Aczél D; Eyüpoglu E; Nagy N; Nagy Á; Krizsán S; Reiniger L; Farkas P; Kozma A; Ádám E; Tasnády S; Réti M; Matolcsy A; Gyenesei A; Mátrai Z; Bödör C
    Int J Cancer; 2020 Jan; 146(1):85-93. PubMed ID: 31180577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Jones D; Woyach JA; Zhao W; Caruthers S; Tu H; Coleman J; Byrd JC; Johnson AJ; Lozanski G
    Leukemia; 2017 Jul; 31(7):1645-1647. PubMed ID: 28366935
    [No Abstract]   [Full Text] [Related]  

  • 6. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
    Lampson BL; Brown JR
    Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
    Wu J; Zhang M; Liu D
    Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BTK in CLL: Beyond Ibrutinib.
    Bond DA; Woyach JA
    Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of
    Quinquenel A; Fornecker LM; Letestu R; Ysebaert L; Fleury C; Lazarian G; Dilhuydy MS; Nollet D; Guieze R; Feugier P; Roos-Weil D; Willems L; Michallet AS; Delmer A; Hormigos K; Levy V; Cymbalista F; Baran-Marszak F;
    Blood; 2019 Aug; 134(7):641-644. PubMed ID: 31243043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
    Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
    Yu H; Truong H; Mitchell SA; Liclican A; Gosink JJ; Li W; Lin J; Feng JY; Jürgensmeier JM; Billin A; Xu R; Patterson S; Pagratis N
    SLAS Discov; 2018 Oct; 23(9):919-929. PubMed ID: 30011241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA
    Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
    Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
    Thompson PA; Ferrajoli A; O'Brien S; Wierda WG; Keating MJ; Burger JA
    Br J Haematol; 2015 Jul; 170(1):125-8. PubMed ID: 25522014
    [No Abstract]   [Full Text] [Related]  

  • 16. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
    Famà R; Bomben R; Rasi S; Dal Bo M; Ciardullo C; Monti S; Rossi F; D'Agaro T; Zucchetto A; Gattei V; Gaidano G; Rossi D
    Blood; 2014 Dec; 124(25):3831-3. PubMed ID: 25498455
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
    Lenz G
    J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
    [No Abstract]   [Full Text] [Related]  

  • 20. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
    Mikudina B; Goodall M; Adler AI
    Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.